- Home
- POR vs BLCO Comparison
POR vs BLCO Comparison
Compare POR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- BLCO
- Stock Information
- Founded
- POR 1889
- BLCO 1853
- Country
- POR United States
- BLCO Canada
- Employees
- POR N/A
- BLCO N/A
- Industry
- POR Electric Utilities: Central
- BLCO Ophthalmic Goods
- Sector
- POR Utilities
- BLCO Health Care
- Exchange
- POR Nasdaq
- BLCO Nasdaq
- Market Cap
- POR 4.9B
- BLCO 4.0B
- IPO Year
- POR N/A
- BLCO 2022
- Fundamental
- Price
- POR $42.33
- BLCO $11.51
- Analyst Decision
- POR Hold
- BLCO Hold
- Analyst Count
- POR 11
- BLCO 12
- Target Price
- POR $45.78
- BLCO $15.59
- AVG Volume (30 Days)
- POR 1.0M
- BLCO 1.1M
- Earning Date
- POR 04-25-2025
- BLCO 04-30-2025
- Dividend Yield
- POR 4.96%
- BLCO N/A
- EPS Growth
- POR 8.87
- BLCO N/A
- EPS
- POR 2.86
- BLCO N/A
- Revenue
- POR $3,439,000,000.00
- BLCO $4,829,000,000.00
- Revenue This Year
- POR $4.88
- BLCO $6.30
- Revenue Next Year
- POR $4.35
- BLCO $5.56
- P/E Ratio
- POR $14.80
- BLCO N/A
- Revenue Growth
- POR 10.79
- BLCO 11.94
- 52 Week Low
- POR $40.05
- BLCO $10.45
- 52 Week High
- POR $49.85
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- POR 47.69
- BLCO 40.20
- Support Level
- POR $41.40
- BLCO $10.83
- Resistance Level
- POR $42.94
- BLCO $11.50
- Average True Range (ATR)
- POR 0.90
- BLCO 0.58
- MACD
- POR 0.06
- BLCO -0.04
- Stochastic Oscillator
- POR 50.80
- BLCO 30.11
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.